Loading...
•
Jun 30, 2024
Black Diamond Therapeutics Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $19.9 million for the second quarter of 2024, with $123.0 million in cash, cash equivalents, and investments, expected to fund operations into Q4 2025.
Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024.
On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and initial Phase 1 data of BDTX-4933 in KRASm NSCLC in Q4 2024.
Upcoming poster presentation at 2024 ESMO Congress in September on treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations.
Cash, cash equivalents, and investments of $123.0 million as of June 30, 2024, expected to be sufficient to fund operations into Q4 of 2025.
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
Black Diamond expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the fourth quarter of 2025.